---
schema_version: "secwatch.filing_event.v1"
accession: "0001022079-26-000097"
form_type: "8-K"
ticker: "DGX"
cik: "0001022079"
company_name: "QUEST DIAGNOSTICS INC"
filed_at: "2026-10-22T10:49:59+00:00"
generated_at: "2026-10-22T10:55:06.101337+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Quest Diagnostics Q3 revenue $3.10B up 10%; adjusted EPS $3.00 up 15.4%; raises FY2026 guidance

## Summary
- Q3 net revenues $3.097B vs $2.816B; Diagnostic Information Services revenue $3.035B, up 10.2% YoY.
- Requisition volume rose 14.5% (organic +14.4%) while revenue per requisition fell 4.2%; reported diluted EPS $2.78, up 28.7%.
- Operating income $479M (15.5% of revenue); adjusted operating income $517M (16.7%); net income attributable to Quest $312M, up 27.6%.
- FY2026 guidance raised: revenue $12.065-$12.105B (prior $11.95-$12.05B), adjusted diluted EPS $11.25-$11.35 (prior $11.05-$11.25), operating cash flow ~$1.90B.
- Announced Quest lab panel with 50+ biomarkers sold via Apple Health app, definitive deal for Northeastern health system outreach lab assets, and AD-Detect pTau217 test launch.

## SEC filing metadata
- accession: 0001022079-26-000097
- form_type: 8-K
- ticker: DGX
- cik: 0001022079
- company_name: QUEST DIAGNOSTICS INC
- filed_at: 2026-10-22T10:49:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1022079/000102207926000097/0001022079-26-000097-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1022079/000102207926000097/dgx-20261022.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001022079-26-000097
- JSON: https://secwatch.observer/filing/0001022079-26-000097.json
- Plain text: https://secwatch.observer/filing/0001022079-26-000097.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.